PAG
URGN icon

Private Advisor Group’s UroGen Pharma URGN Stock Holding History

Private Advisor Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,000
Closed -$78K – 3330
2020
Q2 		$78K Buy
+3,000
New +$73.3K ﹤0.01% 1861

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Advisor Group's URGN Position: Q3 2020 in Review

Private Advisor Group sold out of UroGen Pharma (URGN) in Q3 2020, closing a stake of 3,000 shares — an estimated $78K sold.

Private Advisor Group first reported a position in URGN in Q2 2020 and held it in 1 quarter. The position peaked at $78K in Q2 2020. 80 funds tracked by Wall St. Rank hold URGN as of Q3 2020.

  • Private Advisor Group reported no remaining UroGen Pharma position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 3,000 UroGen Pharma shares in Q3 2020, an estimated $78K.
  • Private Advisor Group first reported a position in UroGen Pharma in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's UroGen Pharma position peaked at $78K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.